Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buspirone Hydrochloride

FDA-approved product (tablet, oral), marketed as Bucapsol, Buspar, Buspirone Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Buspirone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Depressive disorder
  • Generalized anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Azaspirodecanedione derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli41.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buspirone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buspirone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Buspirone for Opioid Tapering

    NCT03521960 · start 2018-05-30

    Registered record
    Registry ID
    NCT03521960
    Conditions
    Opioid-Related Disorders; Dependency (Psychology); Pain, Chronic; Opiate Withdrawal Syndrome
    Interventions
    Buspirone oral capsule; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-30
    Completion
    2020-06-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders; Dependency (Psychology); Pain, Chronic; Opiate Withdrawal Syndrome
    InterventionBuspirone oral capsule; Placebo oral capsule
    PhasePhase 1
    Registry statusCompleted

  • Buspirone in Parkinson's Disease

    NCT02803749 · start 2016-10

    Registered record
    Registry ID
    NCT02803749
    Conditions
    Parkinson Disease; Anxiety
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2019-01-25
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Anxiety
    InterventionBuspirone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease

    NCT02617017 · start 2016-06-17

    Registered record
    Registry ID
    NCT02617017
    Conditions
    Parkinson
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06-17
    Completion
    2023-03-23
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson
    InterventionBuspirone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Buspirone Plus Omeprazole for Functional Dyspepsia

    NCT03444831 · start 2016-03-01

    Registered record
    Registry ID
    NCT03444831
    Conditions
    Dyspepsia
    Interventions
    Buspirone; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03-01
    Completion
    2017-04-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia
    InterventionBuspirone; Placebo Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

    NCT02589340 · start 2016-01

    Registered record
    Registry ID
    NCT02589340
    Conditions
    Parkinson's Disease; Dyskinesias; Movement Disorders
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-01
    Completion
    2021-02-23
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Dyskinesias; Movement Disorders
    InterventionBuspirone; Placebo
    PhasePhase 1
    Registry statusTerminated

  • Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone

    NCT02483598 · start 2015-06

    Registered record
    Registry ID
    NCT02483598
    Conditions
    Gastric Bypass
    Interventions
    Buspirone; Buspirone and Grapefruit Juice
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2018-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Bypass
    InterventionBuspirone; Buspirone and Grapefruit Juice
    PhasePhase 4
    Registry statusTerminated

  • Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

    NCT02458469 · start 2015-05-14

    Registered record
    Registry ID
    NCT02458469
    Conditions
    Spinal Cord Injury; Sleep Disordered Breathing
    Interventions
    Buspirone; Trazodone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-14
    Completion
    2019-04-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Sleep Disordered Breathing
    InterventionBuspirone; Trazodone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type

    NCT02186366 · start 2014-09

    Registered record
    Registry ID
    NCT02186366
    Conditions
    Anxiety Disorders
    Interventions
    Abdominal Massage Therapy; Buspirone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-09
    Completion
    Not recorded
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorders
    InterventionAbdominal Massage Therapy; Buspirone
    PhaseNot applicable
    Registry statusUnknown

  • Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

    NCT01484184 · start 2013-07

    Registered record
    Registry ID
    NCT01484184
    Conditions
    Spinal Cord Injury
    Interventions
    SPINALON (buspirone + levodopa + cardidopa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2015-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury
    InterventionSPINALON (buspirone + levodopa + cardidopa)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

    NCT01850355 · start 2013-07

    Registered record
    Registry ID
    NCT01850355
    Conditions
    Autism Spectrum Disorders; Anxiety
    Interventions
    Buspirone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-07
    Completion
    2024-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorders; Anxiety
    InterventionBuspirone
    PhaseNot applicable
    Registry statusCompleted

  • Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

    NCT02101203 · start 2013-07

    Registered record
    Registry ID
    NCT02101203
    Conditions
    Hypoactive Sexual Desire Disorder
    Interventions
    Placebo; 0.5 mgTestosterone + 10 mg Buspirone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypoactive Sexual Desire Disorder
    InterventionPlacebo; 0.5 mgTestosterone + 10 mg Buspirone
    PhasePhase 2
    Registry statusCompleted

  • Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

    NCT01821690 · start 2013-05-15

    Registered record
    Registry ID
    NCT01821690
    Conditions
    Traumatic Brain Injury
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-05-15
    Completion
    2025-09-26
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTraumatic Brain Injury
    InterventionBuspirone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

    NCT01639157 · start 2012-09

    Registered record
    Registry ID
    NCT01639157
    Conditions
    Cocaine Use Disorders
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorders
    InterventionBuspirone; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

    NCT01641159 · start 2012-08

    Registered record
    Registry ID
    NCT01641159
    Conditions
    Cocaine Dependence
    Interventions
    Buspirone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2013-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence
    InterventionBuspirone; Placebo
    PhasePhase 2
    Registry statusCompleted